Faron Pharmaceuticals Oy (GB:FARN) has released an update.
Faron Pharmaceuticals Ltd., a biopharmaceutical company focused on novel cancer immunotherapies, is set to release its unaudited financial results for the first half of 2024 on August 27. The company will also host a live briefing and Q&A session on August 28, offering both webcast and a limited in-person attendance in Helsinki. Investors and media can find the half-year report and a replay of the briefing on Faron’s website, with the company’s lead asset, bexmarilimab, currently under clinical trials for hematological cancers.
For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.
